Society for Integrative Oncology

INTEGRATED ONCOLOGY NETWORK WELCOMES NEW CHIEF INFORMATION TECHNOLOGY OFFICER

Retrieved on: 
Wednesday, September 27, 2023

NASHVILLE, Tenn., Sept. 27, 2023 /PRNewswire/ -- Integrated Oncology Network (IO Network) is excited to announce the appointment of William Figueroa, a seasoned industry expert, as our new Chief Information Technology Officer. With a track record of transformative leadership in healthcare technology, Figueroa will spearhead our efforts to integrate cutting-edge technology, streamline operations, and enhance patient care across our extensive network of community-based clinics.

Key Points: 
  • NASHVILLE, Tenn., Sept. 27, 2023 /PRNewswire/ -- Integrated Oncology Network (IO Network) is excited to announce the appointment of William Figueroa, a seasoned industry expert, as our new Chief Information Technology Officer.
  • With a track record of transformative leadership in healthcare technology, Figueroa will spearhead our efforts to integrate cutting-edge technology, streamline operations, and enhance patient care across our extensive network of community-based clinics.
  • Integrated Oncology Network is committed to embracing forward-thinking leadership, embodying a dedication to staying at the forefront of healthcare advancements.
  • The appointment of William Figueroa as Chief Information Technology Officer reflects this commitment and sets the stage for an exciting new chapter in our journey towards integrating technology and healthcare to improve the lives of those we serve.

City of Hope receives $100 million gift to create first-of-its-kind national integrative oncology program

Retrieved on: 
Tuesday, September 12, 2023

LOS ANGELES, Sept. 12, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced a $100 million gift from Andrew and Peggy Cherng, philanthropists, co-founders and co-CEOs of Panda Express, to create a first-of-its-kind, national integrative oncology program that brings together Eastern and Western medicine to improve outcomes and quality of life for cancer patients and survivors.  

Key Points: 
  • Integrative oncology is a whole-person approach to cancer care that draws from diverse cultures, particularly traditional Chinese medicine and other Eastern healing traditions.
  • City of Hope will make integrative oncology an evidence-based, interwoven standard of care that supports optimal cancer treatment and survivorship.
  • Within the next year, City of Hope plans to create one of the first integrative oncology fellowships created and led by oncologists.
  • The benefits of integrative oncology will then be extended to patients throughout City of Hope's national cancer care and research system.

DrTalks Announces the Cancer Breakthroughs Summit to Take Place Virtually from October 31 - November 6, 2023

Retrieved on: 
Tuesday, August 1, 2023

CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- DrTalks, a cutting-edge health and wellness platform, is proud to announce the upcoming, free Cancer Breakthroughs Summit. The event will be hosted by Michael Karlfeldt, ND, PhD, a renowned Naturopath and one of the leading experts in treating cancer, alongside Isaac Eliaz, MD, MS, LAc, an esteemed authority in integrative oncology. The virtual summit will be entirely online and is open to everyone.

Key Points: 
  • Join the free online Cancer Breakthroughs Summit, providing unparalleled knowledge and tools to fight cancer.
  • Connect directly with international leaders in integrative oncology, hear inspiring stories from cancer survivors, and explore the numerous options available for cancer treatment.
  • CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- DrTalks , a cutting-edge health and wellness platform, is proud to announce the upcoming, free Cancer Breakthroughs Summit .
  • The Cancer Breakthroughs Summit aims to empower attendees with comprehensive knowledge and tools to win the fight against cancer.

LEADING THE WAY IN INTEGRATIVE ONCOLOGY

Retrieved on: 
Wednesday, July 26, 2023

OVERLAND PARK, Kan., July 26, 2023 /PRNewswire/ -- The Riordan Clinic announces the addition of Dr. Stacy Dunn, ND, LAc, FABNO, FABORM, to its integrative oncology team. She will begin her practice at the Overland Park, Kansas, clinic location on July 31.

Key Points: 
  • OVERLAND PARK, Kan., July 26, 2023 /PRNewswire/ -- The Riordan Clinic announces the addition of Dr. Stacy Dunn, ND, LAc, FABNO, FABORM, to its integrative oncology team.
  • In addition to Dr. Dunn, the Riordan Clinic integrative oncology team also includes Chief Medical Officer Dr. Ron Hunninghake, MD, Dr. Kirsten West, ND, LAc, FABNO, and Laura Vasquez, MSN, APRN, NP-C.
    "Dr. Dunn brings a well-rounded blend of experience to our integrative oncology team.
  • To make an appointment with Dr. Dunn or the Riordan Clinic's other integrative oncology providers, call 1-800-447-7276.
  • Riordan Clinic is a world-renowned, academic medical center that has been leading the world in integrative oncology and complex chronic illness care since 1975.

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

Retrieved on: 
Monday, June 12, 2023

Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website .

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website .
  • The presentation, which details data from a pre-specified interim analysis from the ongoing Phase 1b clinical trial of Omeros’ lead MASP-3 inhibitor OMS906 in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), was identified by EHA’s Scientific Program Committee as one of the top five late-breaking submissions and selected for oral presentation.
  • Also available on Omeros’ website is a second presentation at EHA – Alternative Pathway MASP-3 Inhibitor OMS906: Results from a First-in-Man Phase 1 Study in Healthy Subjects and Study Design of Two Ongoing Clinical Trials in Patients with PNH – by Morag Griffin, MBChB, FRCPath, Consultant in Haematology of St. James University Teaching Hospital, Leeds, United Kingdom.
  • This poster presentation describes findings from a single-ascending dose study evaluating OMS906 safety, pharmacokinetics and pharmacodynamics in healthy subjects.

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Thursday, June 1, 2023

Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.

Key Points: 
  • Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.
  • The presentation abstract (#LB2714) was embargoed by EHA until 16:00 CEST today but now is freely accessible on EHA’s website.
  • Following Dr. Panse’s presentation, Omeros will make available on its website the associated slides.
  • Dr. Griffin’s presentation is scheduled for 18:00-19:00 CEST on Friday, June 9, 2023 and will be available for viewing by registered attendees on the online EHA platform throughout the duration of the congress (June 8-11, 2023).

Matthew Mumber, MD Releases Second Poetry Book: The Attending

Retrieved on: 
Thursday, May 4, 2023

--Donald Revell, author of The English Boat and Drought Adapted Vine.

Key Points: 
  • ROME, May 4, 2023 /PRNewswire/ -- Dr. Matthew Mumber announces the release of his latest book of poetry, The Attending .
  • Over every poem in The Attending, grace–and more specifically, the grace of amazement– presides like a sovereign angel.
  • Matthew Mumber has forwarded a courage and energy to our moment more familiar to readers of Blake and of Traherne than to us beleaguered contemporaries.
  • Matthew Mumber, M.D., practices medicine as a board-certi­fed radiation oncologist with the Harbin Clinic in Rome.

OncoRix's breast cancer integrative solution demonstrated enhanced efficacy when combined with chemotherapy in an ex-vivo model

Retrieved on: 
Thursday, March 30, 2023

HERZLIYA, Israel, March 30, 2023 /PRNewswire/ -- Cannabotech (TASE: CNTC), a biotechnology company that developed OncoRix – an integrative oncology brand, based on Cannabis and functional mushroom extracts, published the results of its study using an ex-vivo model to test its anticancer efficacy on breast cancer tissues. As part of the study, the integrative products were also examined in combination with chemotherapy, including their effects on the tumor environment and immune response.

Key Points: 
  • Among the important findings, OncoRix products showed:
    Synergistic activity in combination with common chemotherapy: increasing the anti-cancer effectiveness of low-concentration chemotherapy and a significantly higher anticancer efficacy in comparison with chemotherapy alone.
  • These findings mean that it would be possible to achieve increased efficiency in killing breast cancer cells while reducing the required chemotherapy doses.
  • In the current experiment, cancer tumors were taken only from patients with breast cancer expressing hormone receptors (luminal breast cancer), considered the most common breast cancer tumors.
  • It should be noted that OncoRix has previously shown a different efficacy in other subtypes of breast cancer.

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

Retrieved on: 
Tuesday, October 11, 2022

On October 7, 2022, Allarity filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022.

Key Points: 
  • On October 7, 2022, Allarity filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022.
  • With this filing, the Company has addressed the cause of the non-compliant status with Nasdaq Listing Rule 5250(c)(1), as previously announced on August 26, 2022 .
  • On October 10, 2022, Nasdaq provided confirmation that upon the filing of the Companys Form 10-Q has regained compliance with Nasdaq Listing Rule 5250(c)(1) and the matter is now closed.
  • "We are very pleased to have completed the necessary Q2 filings and to have regained compliance with Nasdaqs listing requirements, said James G. Cullem, Chief Executive Officer at Allarity.

Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care

Retrieved on: 
Thursday, September 8, 2022

Lugano, Switzerland, September 8, 2022 - Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, in conjunction with Conquer Cancer, the ASCO Foundation, announces today Dr. Rushil V. Patel as the 2022 recipient of the Conquer Cancer - Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care.

Key Points: 
  • Lugano, Switzerland, September 8, 2022 - Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, in conjunction with Conquer Cancer, the ASCO Foundation, announces today Dr. Rushil V. Patel as the 2022 recipient of the Conquer Cancer - Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care.
  • Helsinn established the Anna Braglia Endowed Young Investigator Award (YIA) through an endowment to Conquer Cancer.
  • The Conquer Cancer - Anna Braglia Endowed YIA in Cancer Supportive Care was established in 2016 to honor the life of Anna Braglia, the wife of Helsinn Group Founder and Chairman, Gabriele Braglia, and mother of Helsinn Group Executive Chairman, Riccardo Braglia, following her passing in 2015.
  • Dr. Rushil V. Patel, commented: Receiving the Young Investigator Award for a subject that is so close to my heart is a true honor.